Skip to main content

Table 2 Impact of clofarabine on patients with a high MRD (N=8)

From: French “real life” experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia

MRD evolution

Number (%)

Improvement of one logarithm

1 (12.5%)

Improvement of less than one logarithm

3 (37.5%)

Stable

3 (37.5%)

Non evaluable

1 (12.5%)